Chengdu Rhodiola Bio-Pharmaceutical

Tibet Rhodiola Pharmaceutical Holding Co., Ltd. is a leading Chinese pharmaceutical company specializing in cardiovascular health, biotechnology, and modernized traditional Tibetan medicine. The company is most recognized for its flagship biological product, XinHuo (Recombinant Human Brain Natriuretic Peptide), a Class I innovative drug used for the treatment of acute heart failure. Through its subsidiary, Chengdu Nuodikang Biopharmaceutical, the company operates advanced manufacturing facilities in Chengdu focused on recombinant protein production. Additionally, the company holds the global rights (excluding the US) to the well-known cardiovascular brand Imdur, acquired from AstraZeneca, and maintains a portfolio of Rhodiola-based treatments for coronary heart disease. Listed on the Shanghai Stock Exchange, it is a key player in the integration of ethnic medicine with modern biopharmaceutical standards.